

1/63




Figure 1

2/63




Figure 2A

3/63




Figure 2B

4/63




Figure 3

5/63




Figure 4

6/63




Figure 5

7/63




Figure 6

8/63





Figure 7

9/63





Figure 8A

10/63

**Figure 8B**

11/63




Figure 8C

12/63






Figure 8D

13/63

14:0 LPG



18:0 LPG



18:1 LPG




Figure 9

14/63





Figure 10

15/63



14:0 LPE (30μM): 46.9 ± 15.5 mM (N=3)

Figure 11

16/63




Figure 12

17/63




Figure 13

18/63




Figure 14

19/63




Figure 15

20/63




Figure 16

Concentration-dependent inhibition




Figure 17

22/63

Curve-shift




Figure 18

23/63




Figure 19

24/63






Figure 20

25/63

**Figure 21**

26/63

**Figure 22**

27/63

Control (serum-free)



Figure 23

28/63

18:0 LPG 10 μ M




Figure 24

29/63

18:0 LPG 30 μ M




Figure 25

30/63

14:0 LPA 10 μ M




Figure 26

31/63

14:0 LPA 10 μ M + 18:0 LPG 10 μ M




Figure 27

32/63

14:0 LPA 10 μ M + 18:0 LPG 30 μ M




Figure 28

33/63

Control




Figure 29

34/63

10 μ M 18:0 LPG




Figure 30

35/63

30 μ M 18:0 LPG




Figure 31

36/63

Control




Figure 32

37/63

10 μ M 18:0 LPG




Figure 33

38/63

30 μ M 18:0 LPG






Figure 34

39/63

**Figure 35**

40/63

**Figure 36**

41/63

Control (Serum-free)




Figure 37

42/63

14:0 LPG (30 μ M) : LPA1 antagonist




Figure 38

43/63

18:0 LPG (30 μ M) : LPA1/2 antagonist




Figure 39

44/63

18:1 LPG (30 μ M) : LPA1/2/3 antagonist




Figure 40

45/63

Control (18:1 LPA 10 μ M)




Figure 41

46/63

18:1 LPA 10 μ M + 14:0 LPG (30 μ M)




Figure 42

47/63

18:1 LPA 10 μ M + 18:0 LPG (30 μ M)






Figure 43


48/63

18:1 LPA 10 μ M + 18:1 LPG (30 μ M)**Figure 44**


49/63

**Figure 45**

50/63

**Figure 46**

51/63


**Figure 47**

52/63

	Inhibition (%)	
	Without LPA	With LPA
14:0 LPG (30 μ M)	8%	26% 
18:0 LPG (30 μ M)	41%	37%
18:1 LPG (30 μ M)	29%	39% 

Figure 48

53/63

**Figure 49**

54/63

	Inhibition (%)	
	Without LPA	With LPA
14:0 LPG (30 μ M)	4%	16% 
18:0 LPG (30 μ M)	46%	49%
18:1 LPG (30 μ M)	13%	32% 

Figure 50

55/63



1 μ M 18:1 LPA

Figure 51

56/63





Figure 52

57/63

**Figure 53**

58/63






Figure 54

59/63

**Figure 55**

60/63

**Figure 56**

61/63




Figure 57




Figure 58




Figure 59